Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics reported Q3 2026 results with a net loss of $26.4 million and cash, cash equivalents, and investments of $403.8 million as of September 30, 2026. Clinically, the company announced positive Phase 1 driving-simulation data for GlyphAllo, which did not impair next-morning driving performance, dosed the first patient in the GlyphAgo Phase 2a GAD trial, and kept BUOY-1 Phase 2b MDD enrollment on track with topline data expected 1H 2027. Management expects the cash position to fund operations into 2029 through three mid-to-late-stage data readouts, including a potentially registration-enabling Phase 2/3 trial of GlyphAgo in GAD planned for initiation in 1H 2027.

•7d ago

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Seaport Therapeutics presented the first scientific data from its GlyphAgo Phase 1 program at the ECNP Congress in Munich, showing a statistically significant 6.8-fold increase in agomelatine bioavailability and roughly 10-fold lower PK variability versus unmodified agomelatine. The multi-part trial in 174 healthy volunteers showed dose-dependent exposure, no food effect, and no accumulation over seven days of dosing, with the Glyphed prodrug designed to bypass first-pass liver metabolism and reduce liver enzyme risk. Seaport has initiated a Phase 2a trial of GlyphAgo in generalized anxiety disorder with sleep disturbance (topline early 2028) and plans a Phase 2/3 GAD trial starting in the first half of 2027. PureTech Health, the founding hub company, noted the announcement.

•1mo ago

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Seaport Therapeutics presented detailed Phase 1 pharmacokinetic data for GlyphAgo at the 39th ECNP Congress in Munich, its first scientific presentation of the program. The data confirm a statistically significant 6.8-fold increase in agomelatine bioavailability and roughly 10-fold lower PK variability versus unmodified agomelatine, with no food effect and no accumulation over seven days of dosing. The company believes lower doses reducing hepatic exposure could lessen liver enzyme elevation risk and routine liver monitoring. Seaport has initiated a Phase 2a trial in generalized anxiety disorder with topline expected in early 2028, plus a Phase 2/3 planned for the first half of 2027.

•1mo ago

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Seaport Therapeutics dosed the first patient in a six-week Phase 2a trial in Australia evaluating GlyphAgo (SPT-320) in adults with generalized anxiety disorder and sleep disturbance. The trial is designed as proof-of-pharmacology, measuring effects on sleep via the Insomnia Severity Index and EEG-based sleep-architecture measures, with topline data expected in early 2028. Phase 1 data showed a statistically significant 6.8-fold bioavailability increase versus unmodified agomelatine with no liver-related adverse events; a global Phase 2/3 GAD trial is planned for the first half of 2027 with topline data by end of 2028. PureTech Health (LSE: PRTC), Seaport's founding hub, noted the announcement as part of its hub-and-spoke model.

•1mo ago

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Seaport Therapeutics dosed the first patient in a six-week Phase 2a trial of GlyphAgo (SPT-320) in adults with generalized anxiety disorder and sleep disturbance in Australia. The trial tests two dose levels (16 mg and 32 mg daily) for proof-of-pharmacology using sleep and anxiety endpoints, with topline data expected in early 2028. Phase 1 data showed a statistically significant 6.8-fold bioavailability increase versus unmodified agomelatine with no liver-related adverse events, and a global Phase 2/3 GAD trial is planned for the first half of 2027 with topline by end of 2028.

•1mo ago

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Seaport Therapeutics (Nasdaq: SPTX) reported positive topline results from its Phase 1 Driving Simulation Trial of GlyphAllo (SPT-300), with the primary endpoint met — evening dosing at 375 mg, the highest dose in the Phase 2b BUOY-1 trial, did not impair next-morning driving performance versus placebo on Day 5 after multiple-day dosing. The key secondary endpoint was also met, with a single 250 mg evening dose showing no next-morning driving impairment on Day 2. A 7.5 mg zopiclone positive control produced statistically significant impairment, confirming assay sensitivity, and GlyphAllo was well tolerated with no serious adverse events. Seaport plans to submit the results to the FDA as part of GlyphAllo's development program for major depressive disorder. The potentially registration-enabling Phase 2b BUOY-1 trial is actively enrolling, with topline data expected in the first half of 2027. PureTech Health (LSE: PRTC), Seaport's founding entity, noted the announcement; the data reinforce GlyphAllo's differentiation profile — benefits of allopregnanolone without next-morning driving effects — ahead of the pivotal readout.

•2mo ago

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Seaport Therapeutics reported positive topline results from the Phase 1 Driving Simulation Trial of GlyphAllo, with the trial meeting its primary endpoint — evening dosing at 375 mg did not impair next-morning driving performance versus placebo on Day 5 after multiple-day dosing. The key secondary endpoint was also met, with a single 250 mg evening dose showing no next-morning driving impairment on Day 2. Zopiclone at 7.5 mg impaired driving as expected, confirming assay sensitivity, and GlyphAllo was well-tolerated with no serious adverse events. Seaport plans to submit the results to the FDA as part of the ongoing GlyphAllo development program and is actively enrolling the potentially registration-enabling Phase 2b BUOY-1 trial in major depressive disorder, with topline data expected in the first half of 2027. The findings reinforce GlyphAllo's differentiation as a potential first-in-class oral prodrug of allopregnanolone for MDD ahead of the pivotal readout, though the data come from 33 healthy volunteers rather than patients.

•2mo ago

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics ended the second quarter with $427.3 million in cash and equivalents, providing a runway into 2029 following its May IPO that raised $260 million in gross proceeds. Clinically, the company reported positive Phase 1 data for GlyphAgo, showing a 6.8-fold increase in bioavailability, and plans to initiate Phase 2 trials in the second half of 2026. Enrollment is on track for the Phase 2b BUOY-1 trial of lead candidate GlyphAllo, with topline data expected in the first half of 2027.

•3mo ago

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics reported positive Phase 1 multiple-ascending dose (MAD) data for GlyphAgo, its novel oral prodrug of agomelatine. The trial involved 174 healthy volunteers and showed that seven-day dosing achieved therapeutic exposures with no liver-related adverse events, addressing a key limitation of unmodified agomelatine. GlyphAgo demonstrated a 6.8-fold increase in bioavailability and 10-fold lower PK variability compared to unmodified agomelatine, supporting advancement into two parallel Phase 2 trials for generalized anxiety disorder.

•5mo ago

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics reported Q1 2026 results with a net loss of $25.4 million, driven by increased R&D spend of $21.4 million as its lead programs advance. The company highlighted positive clinical progress: GlyphAgo showed a 6.8-fold increase in bioavailability compared to unmodified agomelatine, potentially avoiding liver toxicity issues, while enrollment in the pivotal Phase 2b BUOY-1 trial for GlyphAllo is on track with topline data expected in H1 2027. Seaport closed an upsized IPO raising $260 million in gross proceeds, bringing total cash and investments to over $470 million and extending its operational runway into 2029. Dr. Sharon Mates, former CEO of Intra-Cellular Therapies, joined the board.

•5mo ago

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics reported positive multiple-ascending dose (MAD) data from its Phase 1 proof-of-concept trial of GlyphAgo in healthy volunteers. The data confirmed favorable safety, tolerability, and pharmacokinetics, with no liver-related adverse events observed across all dose levels. Results support the planned advancement of GlyphAgo into two parallel Phase 2 trials for generalized anxiety disorder, with Phase 2a initiation expected in H2 2026.

•5mo ago